Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...
Le Lézard2d
Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office
Enveric Biosciences ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, ...
Yahoo Finance19d
Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio
“It is extremely encouraging to see the progress being made by Neurocrine across this exciting portfolio of muscarinic agonists and its team’s clear commitment to advancing these novel ...
Yahoo Finance19d
Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio
“It is extremely encouraging to see the progress being made by Neurocrine across this exciting portfolio of muscarinic agonists and its team’s clear commitment to advancing these novel molecules ...
Nature25d
Public biotech 2006—the numbers
Most of the large PIPE financings came early in the year, including $137 million for mAb company Genmab, $83 million for Keryx (a US company located in New York City, developing small molecules ...
Yahoo Finance4d
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
On Monday, Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE: TAK ) to develop and commercialize osavampator (NBI-1065845/TAK-653).